Netherlands Cancer Institute (NKI)

An ongoing, randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST) (2021) Ahrens M, Escudier B, Haanen JBAG, Boleti E, Goupil GM, Grimm MO, Negrier S, et al. Conference contribution Risk-Adjusted Cancer Screening and Prevention (RiskAP): complementing screening for early disease detection by a learning screening based on risk factor (2021) Schmutzler RK, Schmitz-Luhn B, Borisch B, Devilee P, Eccles D, Hall P, Balmaña J, et al. Journal article, Original article Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article Exclusive endocrine therapy or partial breast irradiation for women aged ≥70years with luminal A-like early stage breast cancer (NCT04134598 – EUROPA): Proof of concept of a randomized controlled trial comparing health related quality of life by patient reported outcome measures (2021) Meattini I, Poortmans PM, Marrazzo L, Desideri I, Brain E, Hamaker M, Lambertini M, et al. Journal article Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition (2021) Rogiers A, Da Silva IP, Tentori C, Tondini CA, Grimes JM, Trager MH, Nahm S, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. (2021) Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, et al. Journal article Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. (2021) Eggermont AM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, et al. Journal article Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024] (Annals of Oncology (2021) 32(8) (1015–1024), (S0923753421015532), (10.1016/j.annonc.2021.05.353)) (2021) Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, Petrakova K, et al. Journal article, Erratum Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ (2021) Baudin E, Caplin M, Garcia-Carbonero R, Fazio N, Ferolla P, Filosso PL, Frilling A, et al. Journal article Clinical Characteristics and Outcome of Children With Wagr Syndrome and Wilms Tumor Identified through SIOP-RTSG Registries (2020) Hol JA, Jongmans MCJ, Sudour-Bonnange H, Ramirez-Villar GL, Chowdhury T, Rechnitzer C, Pal N, et al. Conference contribution